Understanding the mechanisms of vascular remodeling could lead to more effective treatments for ischemic conditions. We aimed to compare between the abilities of both human Wharton jelly derived mesenchymal stem cells (hMSCs) and human cord blood endothelial progenitor cells (hEPCs) and CD34⁺ to induce angiogenesis in vitro. hMSCs, hEPCs, and CD34⁺ were isolated from human umbilical cord blood using microbead (MiniMacs). The cells characterization was assessed by flow cytometry following culture and real-time PCR for vascular endothelial growth factor receptor 2 (VEGFR2) and von Willebrand factor (vWF) to prove stem cells differentiation. The study revealed successful isolation of hEPCs, CD34⁺, and hMSCs. The hMSCs were identified by gaining CD29⁺ and CD44⁺ using FACS analysis. The hEPCs were identified by having CD133⁺, CD34⁺, and KDR. The potential ability of hEPCs and CD34⁺ to differentiate into endothelial-like cells was more than hMSCs. This finding was assessed morphologically in culture and by higher significant VEGFR2 and vWF genes expression (p<0.05) in differentiated hEPCs and CD34⁺ compared to differentiated hMSCs. hEPCs and CD34⁺ differentiation into endothelial-like cells were much better than that of hMSCs.

中文翻译：

---

内皮祖细胞和间充质干细胞向内皮样细胞分化潜能的比较评估。

了解血管重塑的机制可能会导致针对缺血性疾病的更有效治疗。我们的目的是比较人沃顿胶冻来源的间充质干细胞（hMSCs）和人脐带血内皮祖细胞（hEPC）和CD34 induce在体外诱导血管生成的能力。使用微珠（MiniMacs）从人脐带血中分离出hMSC，hEPC和CD34 CD。在培养和实时PCR之后，通过流式细胞术评估细胞特征，以检测血管内皮生长因子受体2（VEGFR2）和血管性血友病因子（vWF），以证明干细胞的分化。该研究表明成功分离出了hEPC，CD34 and和hMSC。通过使用FACS分析获得CD29⁺和CD44⁺来鉴定hMSC。hEPC通过具有CD133⁺，CD34⁺和KDR进行鉴定。hEPCs和CD34⁺分化为内皮样细胞的潜在能力比hMSCs高。通过在培养物中进行形态学评估，并通过与分化的hMSC相比，分化的hEPC和CD34β中较高的VEGFR2和vWF基因表达（p <0.05）来评估这一发现。hEPCs和CD34⁺向内皮样细胞的分化要比hMSCs好得多。